Trastuzumab deruxtecan (T-DXd), a HER2-targeting antibody-drug conjugate in combination with osimertinib, is currently under clinical investigation for NSCLC patients harboring HER2 overexpression or amplification following osimertinib treatment. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.